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The use of whole-exome sequencing to disentangle
complex phenotypes
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and Philip Beales1
The success of whole-exome sequencing to identify mutations causing single-gene disorders has been well documented. In
contrast whole-exome sequencing has so far had limited success in the identiﬁcation of variants causing more complex
phenotypes that seem unlikely to be due to the disruption of a single gene. We describe a family where two male offspring of
healthy ﬁrst cousin parents present a complex phenotype consisting of peripheral neuropathy and bronchiectasis that has not
been described previously in the literature. Due to the fact that both children had the same problems in the context of parental
consanguinity we hypothesised illness resulted from either X-linked or autosomal recessive inheritance. Through the use of
whole-exome sequencing we were able to simplify this complex phenotype and identiﬁed a causative mutation (p.R1070*) in the
gene periaxin (PRX), a gene previously shown to cause peripheral neuropathy (Dejerine–Sottas syndrome) when this mutation is
present. For the bronchiectasis phenotype we were unable to identify a causal single mutation or compound heterozygote,
reﬂecting the heterogeneous nature of this phenotype. In conclusion, in this study we show that whole-exome sequencing has
the power to disentangle complex phenotypes through the identiﬁcation of causative genetic mutations for distinct clinical
disorders that were previously masked.
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INTRODUCTION
The utility of whole-exome sequencing (WES) for the identiﬁcation of
known and novel disease genes in families segregating rare Mendelian
forms of disease is now well established. However, this technique is
not as frequently applied to the study of nonsyndromic forms of rare
diseases where the phenotypes are more heterogeneous and it is
unclear whether they result from the action of a single gene, multiple
genes or a complex interaction between genetic and environmental
factors. There is therefore a need to extend the scope of WES to the
wider patient population so that they can beneﬁt from improved
diagnoses and potential therapeutics. To this end we present the data
from our WES analysis of a consanguineous pedigree from Bangladesh
(Figure 1) diagnosed with a complex phenotype of peripheral
neuropathy and bronchiectasis, a phenotype that has not previously
been described in the literature.
Peripheral neuropathies are a heterogeneous group of phenotypes
that may be isolated or multiple. They may have nongenetic causes
such as trauma, toxins or diabetes. Sensory, motor, autonomic nerves
may be affected, and there is a complex classiﬁcation of different
neuropathies. However, most cases of early-onset neuropathies affect-
ing many nerves have an underlying genetic cause. More than 500
different genetic conditions causing peripheral neuropathy are listed
on the London Medical Database. Similarly, bronchiectasis is a term
used to describe a clinicopathological phenotype with multiple routes
to causation. These include local causes such as damage due to
previous infection, foreign body or developmental abnormality, and
systemic conditions which include genetic (such as cystic ﬁbrosis),
immunodeﬁcient (principally antibody deﬁciency) and systemic
inﬂammatory states (such as rheumatoid arthritis). Because of this
complexity, even with intensive investigation, in many cases there is
no known identiﬁable cause.
For this family we hypothesised that, due to the presence of
consanguinity in the parents and the phenotype being present only
in the male offspring the mode of inheritance would be either
X-linked or autosomal recessive. In an attempt to identify the
causative variant(s) we performed WES in two of the offsprings, one
affected and one unaffected (Figure 1; II:2 and II:4, respectively).
MATERIALS AND METHODS
Clinical diagnosis
Regarding respiratory manifestations, the older sibling (Figure 1, II.3)
had a high-resolution computerised tomography scan diagnostic of
bronchiectasis following recurrent chest infections that were slow to
clear, and with persistent changes visible on a chest X-ray. Following
an admission to hospital with RSV bronchiolitis, the younger sibling
(II.2) also had a diagnostic high-resolution computerised tomography
performed (requested given the known bronchiectasis in his brother).
Both have been extensively investigated in line with current British
Thoracic Society guidelines. The clinical diagnosis is therefore one of
bronchiectasis likely secondary to aspiration and gastro-oesophageal
reﬂux. Neither has evidence of airﬂow obstruction (normal FEF25-75,
with FEV1 at 90% and 79% for the older and younger sibling,
1Centre for Translational Omics – GOSgene, UCL Institute of Child Health, University College London, London, UK; 2UCL Respiratory Medicine, UCL Medical School, London, UK;
3Paediatric Respiratory Medicine, Royal London Hospital, Whitechapel, London, UK; 4Department of Clinical Genetics, Great Ormond St Hospital, London, UK
*Correspondence: Dr C Bacchelli, Centre for Translational Omics – GOSgene, UCL Institute of Child Health, University College London, London WC1N 1EH, UK.
Tel: +44 20 79052153; E-mail: c.bacchelli@ucl.ac.uk
Received 27 November 2014; revised 11 March 2015; accepted 24 April 2015; published online 10 June 2015
European Journal of Human Genetics (2016) 24, 298–301
& 2016 Macmillan Publishers Limited All rights reserved 1018-4813/16
www.nature.com/ejhg
respectively) and both are clinically stable with regular chest physio-
therapy, azithromycin antibiotic prophylaxis and acid suppression
with omeprazole.
The neuropathy phenotype was ﬁrst described in sibling II.2 at
20 months of age after he was examined by a clinician due to the
observation that he was not walking but showed no sign of being
dysmorphic, having hypotonia or joint laxity, concerns persisted as he
did not start walking until 34 months of age. He also displayed motor
difﬁculties, such as holding a pen, and was struggling in school. Nerve
conduction studies showed a severe demyelinating polyneuropathy
with slow conduction velocities and a nerve biopsy demonstrated
primary demyelination with onion bulb formation. An MRI scan did
not show any deﬁnite pathology. Myelination and other metabolic
investigations have all been normal whereas genetic testing for
chromosome 17q duplication, P0 and gap junction, protein beta-1
were all normal. The younger sibling (II.3) displays a similar
phenotype, he did not walk until after 24 months of age, he also
had difﬁculties in school and although he did not have nerve
conduction studies, the clinical presentation between the two siblings
is undoubtedly the result of a shared condition.
Linkage analysis
Multipoint parametric linkage analysis was performed on all family
members as described previously.1
WES
WES was performed in house using the Agilent SureSelect v1 (38Mb)
kit (II:2) and the Agilent SureSelect v2 (44Mb) kit (II:4) (Agilent,
Santa Clara, CA, USA) followed by sequencing by Illumina GAIIx
(Illumina, San Diego, CA, USA; UCL Genomics, London, UK) as
2× 75 bp runs, one sample per ﬂowcell lane. Data were aligned to
genome build hg19 using Novoalign v2 with GATK2 used for base
quality score recalibration, indel realignment, duplicate removal, and
to perform SNP and INDEL discovery and genotyping using standard
hard ﬁltering parameters and variant quality score recalibration.3
The resultant vcf ﬁles from both individuals (case (II.2) versus
control (II.4)) were analysed using the Ingenuity Variant Analysis
software (Ingenuity, Redwood City, CA, USA) as described in Table 1.
Following the ﬁltering stage the remaining variants were individu-
ally assessed to ensure they were not located within a segmental
duplication and ﬁnally, the bam ﬁles were inspected using Integrative
Genomics Viewer4 software to conﬁrm the quality of the call.
Sanger sequencing
Standard Sanger sequencing using BigDye v3 chemistry (AppliedBio-
systems, Foster City, CC, USA) and Sequencher analysis software
(Gene Codes Corporation, Ann Arbour, MI, USA) were used to
conﬁrm the presence of each potentially causative mutation and to
perform segregation analysis.
Variant data submission
Veriﬁed disease causing variants were submitted to the ClinVar
database (http://www.ncbi.nlm.nih.gov/clinvar/).
RESULTS
Multipoint linkage analysis identiﬁed four regions of linkage LOD
42.0 (Supplementary Table 1 and Supplementary Figure 2).
Through WES we generated an average of 2.7 gigabases of sequence
and coverage of 70× across the exons of each individual
(Supplementary Table 2). Using Ingenuity Variant Analysis software
with the ﬁlters described (Table 1) we were able to ﬁlter the number of
variants from an initial total of 357 699 to a ﬁnal list of 1 and 13
variants for the peripheral neuropathy and bronchiectasis phenotype
analyses, respectively. Removal of variants from within segmental
Figure 1 Segregation of PRX variant R1070* in consanguineous Bangladeshi pedigree. Electropherograms generated by Sanger sequencing. Affected siblings
(II:2 and II:3) are homozygous T (c.3208C4T; p.R1070*), unaffected siblings (II:1 and II:4) and parents (I:1 and I:2) are heterozygous C/T.
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duplications and bad quality calls resulted in a ﬁnal list of four
variants; one unique to the peripheral neuropathy phenotype and
three for the bronchiectasis phenotype (Table 1).
Of the remaining variants only two were located within genes
functionally related to the phenotype under study; these were periaxin
(PRX) for the peripheral neuropathy and Interleukin-33 (IL33) for
the bronchiectasis. The mutation (ClinVar: SCV000212112) in PRX
was a homozygous nonsense mutation (transcript NM_181882.2;
c.3208C4T; p.R1070*) which was not present in the databases of the
1000Genomes,5 EVS (http://evs.gs.washington.edu/EVS/) or within an
internal database of 451 exomes, however, a single heterozygous
carrier was seen in the ExAC database (http://exac.broadinstitute.org;
November 2014) giving an estimated allele frequency in 61 486
samples of 8.1 × 10-6. The mutation lies within the PRX domain of
the protein and has previously been described in the literature
(chr19.hg19:g.40901051; rs104894708) to cause Charcot–Marie–Tooth
disease type 4 F (CMT4F) and Dejerine–Sottas disease.6–11 Sanger
sequencing conﬁrmed the PRX mutation and showed it segregated
with disease in the family in a recessive manner (Figure 1).
The variant (chr9.hg19:g.6254555) located within the IL33 gene
consisted of an A nucleotide insertion (transcript NM_033439.3: c.612
+2_612+3insA) that was located 2 bp into intron 7 and was predicted
to be a potential splice-site mutation. On closer inspection of this
region it became clear that this insertion was located adjacent to a
homopolymer stretch (poly A) and that there were a number of
polymorphisms ﬂanking this repeat within the dbSNP. Homopolymer
runs are notoriously difﬁcult to map and can result in misaligned
reads, for that reason we chose to Sanger sequence all family members
for this region. The Sanger results (Supplementary Figure 1) revealed
that the splice-site mutation (rs113609242) was a false positive result
which was probably caused by the presence of a variant (rs10975521;
transcript NM_033439.3: c612+15 T4A) at position chr9.hg19:
g.6254568 located at the opposite end of the homopolymer run. This
variant was homozygous non-reference in both the affected individuals
and heterozygous in all the unaffected family members but the public
databases showed it had a population frequency of 420%, ruling it
out as a causative variant. For completeness, we also reviewed all 129
variants from stage IV of the ﬁltering cascade but none were strong
candidates for this phenotype.
DISCUSSION
We present here the results of a study that aimed to identify the
genetic cause of a novel phenotype that included peripheral neuro-
pathy and bronchiectasis. We chose to use a combination of linkage
analysis and WES to identify the variant due its well documented
success in similar circumstances.12
Through this approach we were able to identify what we believe to
be the causative variant (R1070*), in the gene PRX, for the peripheral
neuropathy part of the phenotype displayed in this family. Also, as
PRX is located within a region of positive linkage (LOD= 2.1;
Supplementary Table 1) on chromosome 19q13.2 we are able to rule
out the possibility that this part of the phenotype is due to an X-linked
variant.
The gene PRX codes for periaxin which encodes two isoforms,
L- and S-periaxin, which are structural membrane-associated proteins
mainly expressed by myelinating Schwann cells in the peripheral
nervous system (PNS). They are required for proper maintenance of
the peripheral myelin sheath and Schwann cell compartmentalisation
with their integral role reﬂected in the observation that they account
for 16% of PNS myelin protein by weight.13 In PRX-null mice the
nerve ﬁbres appear grossly normal but there is disruption of the
cytoplasmic bands (Cajal bands) and impaired Schwann cell elonga-
tion during nerve growth which leads to a reduction in nerve
conduction velocity and causes focal hypermyelination and demyeli-
nation which are hallmarks of the CMT4F phenotype.14
A number of PRX variants have been described in the literature,6,7,9
including the variant we identiﬁed (R1070*).8,10,11 To date the R1070*
variant has been found in a number of Japanese CMT4F patients and
in one Turkish patient but this is the ﬁrst report of variant in a patient
of Bangladeshi origin.
Our analysis of the IL33 variant (rs113609242) showed that this was
a false positive result. This ﬁnding highlights the challenges that still
persist in WES analyses and demonstrates the need to verify any
potential variant with a second method.
That we were unable to identify a causative variant to describe the
presence of the bronchiectasis phenotype is not entirely surprising, the
term bronchiectasis refers to a syndrome that has numerous potential
causes most of which are not identiﬁable through WES on a single
family.
In summary we demonstrate the utility of WES to disentangle a
complex disease phenotype of peripheral neuropathy and bronchiec-
tasis. We have identiﬁed the causative variant (R1070*) in the gene
PRX that is a known cause of Dejerine–Sottas syndrome, which
explains the peripheral neuropathy phenotype; however, we have been
unable to identify a single causative variant for the bronchiectasis
phenotype and suggest that this likely reﬂects the complex aetiology of
this phenotype.
This ﬁnding offers hope to those patients who do not exhibit a
classic disease phenotype, for whatever reason, that in some cases,
through the application of WES, their phenotype can be broken down
into its constitutive parts and causative variants can be found that
explain speciﬁc features. The identiﬁcation of these speciﬁc phenotypic
features will allow their targeted treatment, where therapies are
available, which will have a positive impact on patient care and more
generally it will lead to a better understanding of the illness holistically.
We believe there are likely to be a great many patients who are
currently undiagnosed who would beneﬁt from the use of WES to
disentangle their complex phenotypes to identify known disease genes.
The potential to improve the prognosis of such patients makes the use
of WES a very cost-effective strategy in the clinic.15
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Table 1 Variant numbers from whole-exome data following ﬁltering
cascade
Filter Variants Genes
Start 357 699 17704
I: Conﬁdence 114 411 15605
II: Common variants 20 104 5773
III: Predicted deleterious 880 558
IV: Genetic analysis 129 58
V: Biological context (peripheral neuropathy) 1 1
VI: Biological context (bronchiectasiaa) 3 3
Filtering cascade as implemented in Ingenuity Variant Analysis, detailed descriptions of the
ﬁltering parameters are given in Supplementary Information.
a10 variants in three genes were subsequently removed due to their location within segmental
duplications.
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